The observation that different FGFR2 mutants in ICC nearly all promote tumor growth, invasion, and metastasis but respond differently to FGFR-selective small molecule kinase inhibitors (SMKIs) implies the need for personalized treatment strategies based on the specific FGFR2 mutation profile of each patient. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.